Add BrightSurf on Google Email

Science News for November 6, 2022


Bivalirudin found to be safer and more effective than heparin for treating heart attack patients undergoing percutaneous coronary intervention

A new study has shown that bivalirudin is a safer and more effective anticoagulant than heparin for treating heart attack patients. The trial found that bivalirudin significantly reduced death, major bleeding, and thrombosis in patients undergoing percutaneous coronary intervention.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateNov 6, 2022

Intermountain study finds follow-up care with medication, testing after heart attack can prevent 94% of patients from having second cardiac event or death

A new study by Intermountain Healthcare found that following up a cardiac event with a statin prescription and cholesterol measuring blood test prevents 94% of patients from having or dying from a second cardiovascular event. Patients without follow-up care were at a 60% risk, compared to just 6% for those who received treatment.

SourceIntermountain Healthcare·TypeObservational study·DateNov 6, 2022

Artificial intelligence could help ease hospital pressures

A new AI technology has been developed to automatically diagnose lung diseases such as tuberculosis and pneumonia, freeing up radiographers and reducing waiting times for test results. The system, which uses X-ray imaging and deep learning algorithms, achieved a 98% accuracy rate during extensive testing.

SourceUniversity of the West of Scotland·JournalComputer Methods and Programs in Biomedicine·TypeComputational simulation/modeling·DateNov 6, 2022

Study Finds Patients Without Standard Modifiable Heart Risk Factors Are Common and More Likely to Fare Better After Heart Attack Than Patients with Known Factors

Researchers at Intermountain Healthcare discovered that patients without standard modifiable heart risk factors who experience a heart attack fare better, with lower rates of revascularization procedures and subsequent major cardiac events. This finding highlights the need to identify patients at risk for an event before it happens.

SourceIntermountain Healthcare·TypeObservational study·DateNov 6, 2022

Clinical trial finds novel therapy markedly reduced lipoprotein(a) levels in people with cardiovascular disease

Researchers at Brigham and Women's Hospital found that olpasiran, a small interfering RNA drug, significantly reduces lipoprotein(a) levels in patients with established cardiovascular disease. The treatment was associated with minimal serious side effects apart from injection site reactions.

SourceBrigham and Women's Hospital·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 6, 2022

Radiation effect simulation software developed for accumulation mechanisms study of radiation damage in nanocrystalline materials

Researchers developed a simulation software to study radiation damage accumulation mechanisms in nanocrystalline materials. The results showed improved radiation resistance due to high grain boundary density, which serves as sinks for radiation-induced vacancies and self-interstitial atoms.

IHMT-CSF1R-833 discovered as potent and selective CSF1R inhibitor

Researchers at Hefei Institutes of Physical Science, Chinese Academy of Sciences, have discovered a potent and selective colony stimulating factor 1 receptor kinase inhibitor. The new compound, IHMT-CSF1R-833, shows high selectivity over human kinases and suppresses tumor-associated macrophage survival and activation.

SourceHefei Institutes of Physical Science, Chinese Academy of Sciences·JournalEuropean Journal of Medicinal Chemistry·DateNov 6, 2022